IFN signature determines responder status on B cell depletion in rheumatoid arthritis patients

Authors :: H G Raterman
C.T.M. van der Pouw Kraan
Saskia Vosslamber
Cornelis L. Verweij
B A C Dijkmans
Michael T. Nurmohamed
W.F. Lems
A E Voskuyl
Marco W.J. Schreurs
Pathology
Rheumatology
Molecular cell biology and Immunology
CCA - Innovative therapy
Source :: Vosslamber, S, Raterman, H G, Schreurs, M W J, van der Pouw Kraan, C T M, Nurmohamed, M T, Lems, W F, Dijkmans, B A C, Voskuyl, A E & Verweij, C L 2010, ' Ifn Signature Determines Responder Status on B Cell Depletion in Rheumatoid Arthritis Patients ', Annals of the Rheumatic Diseases, vol. 69, pp. A30 . https://doi.org/10.1136/ard.2010.129585d, Annals of the Rheumatic Diseases, 69. BMJ Publishing Group
Publication Year :: 2010
Publisher :: BMJ, 2010.
Abstract: B cells are supposed to play an important role in rheumatoid arthritis (RA). Accordingly, rituximab, a chimeric monoclonal antibody against CD20, effectively depletes B cells ameliorates disease although a subset of patients don't respond. We aimed to identify biomarkers and biological …

Subjects :: CD20
biology
business.industry
medicine.drug_class
Immunology
Disease
medicine.disease
Monoclonal antibody
General Biochemistry, Genetics and Molecular Biology
B cell depletion
Rheumatology
hemic and lymphatic diseases
Rheumatoid arthritis
medicine
biology.protein
Immunology and Allergy
Rituximab
business
medicine.drug

Tools